Opportunities and challenges associated with the evaluation of chimeric antigen receptor T cells in real-life | Zendy

Eoin McGrath | Zendy; Christian Chaban | Zendy; Sofie Terwel | Zendy; Chiara Bonini | Zendy; Jürgen Kuball | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Opportunities and challenges associated with the evaluation of chimeric antigen receptor T cells in real-life

Author(s) -

Eoin McGrath,

Christian Chaban,

Sofie Terwel,

Chiara Bonini,

Jürgen Kuball

Publication year - 2020

Publication title -

current opinion in oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.297

H-Index - 95

eISSN - 1080-8140

pISSN - 1040-8746

DOI - 10.1097/cco.0000000000000665

Subject(s) - chimeric antigen receptor , computational biology , antigen , computer science , microbiology and biotechnology , biology , immunology , immunotherapy , immune system

With the approval of the first chimeric antigen receptor (CAR)-T cell products on the market, the European Medicines Agency (EMA) required market authorization holders (MAHs) to monitor the long-term efficacy and safety of CAR-T cells for 15 years after administration. In 2019, the cellular therapy module of the European Society for Blood and Marrow Transplantation (EBMT) registry received a positive qualification opinion from the EMA indicating that the registry fulfills the essential needs to capture such data. We investigated its broader implication.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research